Goldman Sachs analyst Chris Shibutani maintains Revolution Medicines (NASDAQ:RVMD) with a Neutral and raises the price target from $20 to $23.
Goldman Sachs Maintains Neutral on Revolution Medicines, Raises Price Target to $23
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.